Cancer Letters

Cancer Letters

Volume 348, Issues 1–2, 28 June–1 July 2014, Pages 77-87
Cancer Letters

CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial–mesenchymal transition

https://doi.org/10.1016/j.canlet.2014.03.008Get rights and content

Abstract

Liver metastases represent the major cause of death in patients with colorectal cancer (CRC). Recent studies have suggested that the chemotactic responses of tumor cells are necessary for metastatic spread to the liver, and CCL20 and CXCL8 have a strong association with CRC metastasis. The aim of our study was to identify the mechanisms by which CCL20 and CXCL8 synergize to promote metastatic progression and evaluated their potential as prognostic markers for CRC patients. The abilities of CCL20 and CXCL8 to promote CRC cell progression and epithelial–mesenchymal transition (EMT) phenotype were analyzed in vitro. Possible signaling pathways were investigated with specific pathway inhibitors and small interfering RNA (siRNA). 213 Patients with CRC who underwent surgery were enrolled for analysis of CCL20, CXCL8 and E-cadherin expressions in tumor tissues. Prognostic factors were then identified. CCL20 or CXCL8 alone was not sufficient to induce complete EMT in CRC cells, but both of them could coordinately induce EMT-like phenotype that was required to maintain CRC cell proliferation, migration and invasion. PI3K/AKT-ERK1/2 pathway crosstalk was demonstrated to be responsible for this process. Coexpression of CCL20 and CXCL8 was negatively correlated with E-cadherin expression in human CRC tissues. CRC patients with coexpression of CCL20 and CXCL8 were more likely to develop liver metastases and both coexpression was an independent high-risk factor for a most poor prognosis. CCL20 and CXCL8 synergize to promote CRC metastatic progression by coordinated induction of EMT via PI3K/AKT-ERK1/2 signaling axis. Detection of both coexpressions can be used to predict clinical outcomes in CRC patients.

Introduction

Colorectal cancer (CRC) is the third most frequent cancer worldwide and the second leading cause of cancer-related death in the developed countries [1]. Approximately 50% of CRC patients die from distant metastases within 6 years of the initial diagnosis, and the liver is the predominant and often the only organ for distant metastasis [2]. Recent studies in CRC have suggested that the chemotactic responses of tumor cells are necessary for metastatic spread to the liver, and chemokines as well as their receptors, in particular CCL20/CCR6 and CXCL8/CXCR1/2, play an important role in the metastatic process. CCL20 is the only chemokine known to interact with the chemokine receptor CCR6 [3], [4], [5], and expressed mainly in mucosa-associated and lymphoid tissues and the liver [5]. CCL20 and CCR6 are expressed predominantly in the microenvironment of CRC tumors [6], [7], [8], [9], [10]. A strong association has been found between CCL20/CCR6 staining intensity in CRC samples and the development of synchronous liver metastases [6], [7], [8]. Stimulation of colon cancer cells by CCL20 has been shown to result in signaling events associated with cell proliferation, adhesion and migration [11]. In a murine model, stimulation of CCR6-expressing plasmocytoma cells with CCL20 before intravenous application resulted in a marked increase in their homing to the liver [12]. CXCL8, also referred to as interleukin-8 (IL-8), stimulated the migratory capacity of a distinct set of leukocytes [13]. Increased expression of CXCL8 has been detected in the tumor microenvironment and blood of CRC patients [14], [15], [16], [17], [18], [19], [20], [21], [22]. Overexpression of CXCL8 promotes tumor growth, progression, and metastasis [16], [17], [18], [19], and is associated with tumor size, tumor grading, depth of infiltration, liver metastasis and survival in CRC [15], [16], [17], [18], [19], [22].

To date, however, the precise mechanisms by which these chemokines determine tumor cell detachment and migration away from the primary tumor tissues remain to be established. Over the past decade, accumulating evidence has shown that the epithelial–mesenchymal transition (EMT) is a pathological process contributing to cancer progression, particularly to cancer invasion, dissemination, and metastasis [23]. While epithelial cells undergo EMT, loss of the epithelial marker E-cadherin (E-cad) and concomitant expression of distinct mesenchymal markers like vimentin (Vim) and beta-catenin play a vital role in this reversible transdifferentiation. Therefore, the EMT provides a mechanism for carcinoma cells to acquire a more aggressive phenotype [23].

Several chemokines for induction of EMT in epithelial tumor cells has been documented, such as CXCL12 for oral squamous cell carcinoma cells B88 and HNt [24], CXCL16 for CRC cell HT29 [25], and CCL18 or CXCL8 for breast cancer cells [26], [27], and CXCL8 for nasopharyngeal carcinoma cells [28]. However, CCL20 or CXCL8-induced EMT in CRC cells has not been reported. In the present study, we demonstrated for the first time that CCL20 or CXCL8 alone was not sufficient to induce complete EMT in human CRC cells, but both of them could jointly induce EMT-like phenotype that was required to maintain CRC cell proliferation, migration and invasion. We further found that the phosphatidylinositol 3-kinase (PI3K)/AKT-ERK1/2 pathway crosstalk mediated by CCL20 and CXCL8 appeared to be responsible for the EMT in the CRC cells. Furthermore, clinical evidence showed that there was a strong association of the coexpression of CCL20 and CXCL8 with the loss of E-cadherin expression in CRC tissues. Patients with CRC who had coexpression of CCL20 and CXCL8 were more likely to develop liver metastases and had a most poor prognosis. The present data indicate that CCL20 and CXCL8 synergize to promote CRC progression and metastasis by collaborative induction of EMT via PI3K/AKT-ERK1/2 crosstalk, therefore, detection of both coexpression can be used to predict patient outcomes, and targeting both CCL20 and CXCL8 or the PI3K/AKT pathway could be highly valuable for the therapy of recurrent or metastatic CRC.

Section snippets

Patients and sample collection

Two hundred thirteen patients with CRC at the Colorectal Cancer Clinical Research Center, Third Affiliated Hospital, Kunming Medical University (Kunming, China) between February 2003 and May 2005 were enrolled onto this study. The median age of patients at the time of admission was 62 years, range 21–79 years. All the patients underwent radical resection of the primary tumor with regional lymph node dissection. All diagnoses of adenocarcinoma were confirmed histopathologically, and the paraffin

Both CCL20 and CXCL8 coordinately induced EMT-like phenotype in colon cancer cells

CCL20 or CXCL8 alone at a concentration of 100 ng/mL for a period of 48 h was not enough to induce an EMT-like phenotype in SW480 cells, but after cotreatment with both chemokines at the same concentration, most cells not only changed to a spindle-shaped, elongated morphology, but also exhibited a loose association and occasional misorientation compared to the closely contacted monolayer, polygon cobblestone-like cells (Fig. 1A). Concomitant expression of epithelial and mesenchymal markers is often

Discussion

Chemokines have been demonstrated to be involved in the pathogenesis and metastasis of tumors [36]. In CRC, the tumor cells selectively upregulate expression of some chemokines and chemokine receptors, providing a basis for efficient autocrine and paracrine loops [37], [38]. Multiple clinical studies implicate chemokines in the development, progression, and metastasis of CRC [39]. However, almost all of these studies focused respectively on a single chemokine involvement and did not address the

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements

This work was supported by Grants from the National Natural Science Foundation of China, China (30960445), Joint Special Funds for the Department of Science and Technology of Yunnan Province-Kunming Medical University (2012FB071) and Funds for Equipped Research Institutions of Yunnan Provincial Health Department, China (2010NS092; 2011WS077; 2011WS076). The use of human tissue samples and clinical data was approved by the ethics committee of Third Affiliated Hospital, Kunming Medical

References (58)

  • A. Jemal et al.

    Global cancer statistics

    CA Cancer J. Clin.

    (2011)
  • D. Holzel et al.

    Colorectal cancer metastasis. Frequency, prognosis, and consequences

    Chirurg

    (2009)
  • P. Ghadjar et al.

    Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer

    J. Clin. Oncol.

    (2006)
  • C. Rubie et al.

    Involvement of chemokine receptor CCR6 in colorectal cancer metastasis

    Tumour Biol.

    (2006)
  • V.O. Frick et al.

    CCR6/CCL20 chemokine expression profile in distinct colorectal malignancies

    Scand. J. Immunol.

    (2013)
  • C. Rubie et al.

    Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases

    World J. Gastroenterol.

    (2011)
  • B. Vicinus et al.

    MiR-21 and its target gene CCL20 are both highly overexpressed in the microenvironment of colorectal tumors: significance of their regulation

    Oncol. Rep.

    (2013)
  • C.C. Yang et al.

    Chemokine receptor CCR6 transduces signals that activate p130Cas and alter cAMP-stimulated ion transport in human intestinal epithelial cells

    Am. J. Physiol. Cell Physio.

    (2004)
  • J. Dellacasagrande et al.

    Liver metastasis of cancer facilitated by chemokine receptor CCR6

    Scand. J. Immunol.

    (2003)
  • D.J. Waugh et al.

    The interleukin-8 pathway in cancer

    Clin. Cancer Res.

    (2008)
  • P.K. Baier et al.

    Chemokines in human colorectal carcinoma

    Anticancer Res.

    (2005)
  • D. Doll et al.

    Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival

    Int. J. Colorectal. Dis.

    (2010)
  • Y. Ning et al.

    Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models

    Int. J. Cancer

    (2011)
  • C. Rubie et al.

    Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer

    World J. Gastroenterol.

    (2007)
  • A. Li et al.

    Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials

    Clin. Cancer Res.

    (2001)
  • Y.S. Lee et al.

    Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis

    Br. J. Cancer

    (2012)
  • J. Dimberg et al.

    DNA promoter methylation status and protein expression of interleukin-8 in human colorectal adenocarcinomas

    Int. J. Colorectal. Dis.

    (2012)
  • T. Kantola et al.

    Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma

    Br. J. Cancer

    (2012)
  • J.W. Choi et al.

    Proteomic and cytokine plasma biomarkers for predicting progression from colorectal adenoma to carcinoma in human patients

    Proteomics

    (2013)
  • Cited by (101)

    • Role of chemokines in HPV-induced cancers

      2022, Seminars in Cancer Biology
    • Utilizing chemokines in cancer immunotherapy

      2022, Trends in Cancer
      Citation Excerpt :

      It is normally induced at sites of inflammation, thereby recruiting neutrophils and granulocytes [30]. In cancer, CXCL8 promotes tumor progression, epithelial–mesenchymal transition (EMT), and recruitment of MDSCs [31–33], with high serum levels correlating with poor prognosis in breast cancer patients [34]. Preclinical studies have shown that CXCL8 blockade with HuMax-IL8 reduces EMT and recruitment of MDSCs to the tumor site [27].

    View all citing articles on Scopus
    1

    These authors contributed equally to this work.

    View full text